Dengue Fever Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major dengue fever markets are expected to exhibit a CAGR of 10.21% during 2024-2034.
The dengue fever market has been comprehensively analyzed in IMARC's new report titled "Dengue Fever Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Dengue fever refers to a mosquito-borne tropical illness caused by the dengue virus (DENV). The virus is passed to humans through the bites of infected female mosquitoes. After the incubation period of 4–10 days, the patient may experience a range of symptoms. Some of the characteristic indications of this condition include a high fever, severe headache, muscle and joint pains, pain behind the eyes, nausea, vomiting, swollen glands, a rash, etc. In rare cases, the disease can develop into serious forms, like dengue shock syndrome, which can cause bleeding, blood plasma leakage, and a low platelet count. The diagnosis of this ailment is typically made through a combination of the patient's clinical symptoms, travel history, and laboratory tests. Molecular analysis, including reverse transcription polymerase chain reaction (RT-PCR), is also utilized to detect the presence of the virus's genetic material in a person's blood. This investigation can help to confirm a diagnosis within the first week of illness. Additionally, the healthcare provider may perform a complete blood count to evaluate the levels of different blood cells, such as platelets, that might indicate the disease.
The escalating cases of viral infections, which cause microorganisms to enter the bloodstream and replicate in the human body, are primarily driving the dengue fever market. Additionally, the rising prevalence of poor waste management and inadequate sanitation that can lead to an increase in mosquito breeding sites, thereby facilitating the spread of the virus, is also creating a positive outlook for the market. Moreover, the widespread adoption of effective analgesics, such as acetaminophen and tramadol, since they help to manage symptoms of the ailment, including fever, headache, and muscle and joint pain, is further bolstering the market growth. Apart from this, the inflating application of intravenous fluids to treat patients who cannot tolerate oral intake is acting as another significant growth-inducing factor. This therapy prevents dehydration and supports vital organ function by restoring fluid balance and maintaining electrolyte levels during the course of the illness. Additionally, the emerging popularity of mosquito repellent topical creams that contain a higher concentration of N, N-diethyl-meta-toluamide, or picaridin to provide longer-lasting protection against the infection is expected to drive the dengue fever market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the dengue fever market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for dengue fever and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the dengue fever market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the dengue fever market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the dengue fever market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current dengue fever marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the dengue fever market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the dengue fever market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the dengue fever market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of dengue fever across the seven major markets?
What is the number of prevalent cases (2018-2034) of dengue fever by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of dengue fever by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with dengue fever across the seven major markets?
What is the size of the dengue fever patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of dengue fever?
What will be the growth rate of patients across the seven major markets?
Dengue Fever: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for dengue fever drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the dengue fever market?
What are the key regulatory events related to the dengue fever market?
What is the structure of clinical trial landscape by status related to the dengue fever market?
What is the structure of clinical trial landscape by phase related to the dengue fever market?
What is the structure of clinical trial landscape by route of administration related to the dengue fever market?
The dengue fever market has been comprehensively analyzed in IMARC's new report titled "Dengue Fever Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Dengue fever refers to a mosquito-borne tropical illness caused by the dengue virus (DENV). The virus is passed to humans through the bites of infected female mosquitoes. After the incubation period of 4–10 days, the patient may experience a range of symptoms. Some of the characteristic indications of this condition include a high fever, severe headache, muscle and joint pains, pain behind the eyes, nausea, vomiting, swollen glands, a rash, etc. In rare cases, the disease can develop into serious forms, like dengue shock syndrome, which can cause bleeding, blood plasma leakage, and a low platelet count. The diagnosis of this ailment is typically made through a combination of the patient's clinical symptoms, travel history, and laboratory tests. Molecular analysis, including reverse transcription polymerase chain reaction (RT-PCR), is also utilized to detect the presence of the virus's genetic material in a person's blood. This investigation can help to confirm a diagnosis within the first week of illness. Additionally, the healthcare provider may perform a complete blood count to evaluate the levels of different blood cells, such as platelets, that might indicate the disease.
The escalating cases of viral infections, which cause microorganisms to enter the bloodstream and replicate in the human body, are primarily driving the dengue fever market. Additionally, the rising prevalence of poor waste management and inadequate sanitation that can lead to an increase in mosquito breeding sites, thereby facilitating the spread of the virus, is also creating a positive outlook for the market. Moreover, the widespread adoption of effective analgesics, such as acetaminophen and tramadol, since they help to manage symptoms of the ailment, including fever, headache, and muscle and joint pain, is further bolstering the market growth. Apart from this, the inflating application of intravenous fluids to treat patients who cannot tolerate oral intake is acting as another significant growth-inducing factor. This therapy prevents dehydration and supports vital organ function by restoring fluid balance and maintaining electrolyte levels during the course of the illness. Additionally, the emerging popularity of mosquito repellent topical creams that contain a higher concentration of N, N-diethyl-meta-toluamide, or picaridin to provide longer-lasting protection against the infection is expected to drive the dengue fever market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the dengue fever market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for dengue fever and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the dengue fever market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the dengue fever market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the dengue fever market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current dengue fever marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the dengue fever market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the dengue fever market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the dengue fever market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of dengue fever across the seven major markets?
What is the number of prevalent cases (2018-2034) of dengue fever by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of dengue fever by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with dengue fever across the seven major markets?
What is the size of the dengue fever patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of dengue fever?
What will be the growth rate of patients across the seven major markets?
Dengue Fever: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for dengue fever drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the dengue fever market?
What are the key regulatory events related to the dengue fever market?
What is the structure of clinical trial landscape by status related to the dengue fever market?
What is the structure of clinical trial landscape by phase related to the dengue fever market?
What is the structure of clinical trial landscape by route of administration related to the dengue fever market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 DENGUE FEVER - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 DENGUE FEVER - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 DENGUE FEVER - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 DENGUE FEVER - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 DENGUE FEVER - UNMET NEEDS
10 DENGUE FEVER - KEY ENDPOINTS OF TREATMENT
11 DENGUE FEVER - MARKETED PRODUCTS
11.1 List of Dengue Fever Marketed Drugs Across the Top 7 Markets
11.1.1 Dengvaxia (Dengue vaccine tetravalent) - Sanofi
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 DENGUE FEVER - PIPELINE DRUGS
12.1 List of Dengue Fever Pipeline Drugs Across the Top 7 Markets
12.1.1 V 181 - Merck
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 JNJ-1802 - Janssen
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. DENGUE FEVER - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. DENGUE FEVER – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 DENGUE FEVER - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Dengue Fever - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast 2024-2034)
15.2.2 Dengue Fever - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Dengue Fever - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Dengue Fever - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034
15.3.3 Dengue Fever - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Dengue Fever - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Dengue Fever - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Dengue Fever - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Dengue Fever - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Dengue Fever - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Dengue Fever - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Dengue Fever - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Dengue Fever - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Dengue Fever - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Dengue Fever - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Dengue Fever - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Dengue Fever - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Dengue Fever - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Dengue Fever - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Dengue Fever - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Dengue Fever - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Dengue Fever - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Dengue Fever - Access and Reimbursement Overview
16 DENGUE FEVER - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 DENGUE FEVER MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 DENGUE FEVER MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 DENGUE FEVER - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 DENGUE FEVER - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 DENGUE FEVER - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 DENGUE FEVER - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 DENGUE FEVER - UNMET NEEDS
10 DENGUE FEVER - KEY ENDPOINTS OF TREATMENT
11 DENGUE FEVER - MARKETED PRODUCTS
11.1 List of Dengue Fever Marketed Drugs Across the Top 7 Markets
11.1.1 Dengvaxia (Dengue vaccine tetravalent) - Sanofi
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 DENGUE FEVER - PIPELINE DRUGS
12.1 List of Dengue Fever Pipeline Drugs Across the Top 7 Markets
12.1.1 V 181 - Merck
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 JNJ-1802 - Janssen
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. DENGUE FEVER - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. DENGUE FEVER – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 DENGUE FEVER - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Dengue Fever - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast 2024-2034)
15.2.2 Dengue Fever - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Dengue Fever - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Dengue Fever - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034
15.3.3 Dengue Fever - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Dengue Fever - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Dengue Fever - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Dengue Fever - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Dengue Fever - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Dengue Fever - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Dengue Fever - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Dengue Fever - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Dengue Fever - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Dengue Fever - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Dengue Fever - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Dengue Fever - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Dengue Fever - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Dengue Fever - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Dengue Fever - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Dengue Fever - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Dengue Fever - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Dengue Fever - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Dengue Fever - Access and Reimbursement Overview
16 DENGUE FEVER - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 DENGUE FEVER MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 DENGUE FEVER MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
